Voyager Therapeutics (NASDAQ:VYGR) CFO Nathan Jorgensen Sells 4,668 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CFO Nathan Jorgensen sold 4,668 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $3.77, for a total value of $17,598.36. Following the completion of the transaction, the chief financial officer owned 151,416 shares in the company, valued at approximately $570,838.32. The trade was a 2.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Voyager Therapeutics Stock Performance

NASDAQ VYGR traded up $0.03 on Friday, hitting $4.26. 26,299 shares of the stock traded hands, compared to its average volume of 581,896. The business’s fifty day moving average is $3.86 and its two-hundred day moving average is $4.11. Voyager Therapeutics, Inc. has a 12 month low of $2.64 and a 12 month high of $5.55. The firm has a market capitalization of $236.58 million, a price-to-earnings ratio of -1.97 and a beta of 1.30.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ethic Inc. purchased a new stake in shares of Voyager Therapeutics in the second quarter worth $123,000. Los Angeles Capital Management LLC bought a new position in Voyager Therapeutics in the 2nd quarter worth about $50,000. Two Sigma Investments LP purchased a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $657,000. UBS Group AG boosted its position in shares of Voyager Therapeutics by 3.9% during the 3rd quarter. UBS Group AG now owns 473,100 shares of the company’s stock valued at $2,209,000 after acquiring an additional 17,558 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Voyager Therapeutics by 682.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 42,339 shares of the company’s stock valued at $198,000 after acquiring an additional 36,928 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on VYGR. HC Wainwright dropped their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.75.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.